Permission: You will first need to give your consent, or permission, to join the study by reading the patient information sheet and signing the Informed Consent Form.
Check eligibility: The study doctor will then ask you about your symptoms of dermatomyositis, health history, and any medicines you take. You will also have a checkup and some tests to make sure the study is right for you.
If eligible, you will be placed by chance (like flipping a coin) into a study treatment group. Neither you nor the study team will know which group you are in. This helps to keep the study fair.
If eligible and you choose to continue into the extension period, you will take brepocitinib once daily for 52 weeks.
You may have one last visit for tests 4 weeks after your final dose of study drug.
Take 3 tablets by mouth every morning after breakfast (you can take the tablets with or without food). While taking the study medicine, you will also continue all other therapies such as physical therapy, weight management and/or exercise routine as directed by your doctor.